演題詳細

一般口演 / Oral Session

一般口演 101 (Oral Session 101) :悪性リンパ腫:PET/CT・合併症・予後因子

print

日程
2013年10月13日(日)
時間
16:00 - 17:00
会場
第8会場 / Room No.8 (ロイトン札幌 2F ハイネス)
座長・司会
伊豆津 宏二 (Koji Izutsu):1
1:虎の門病院 血液内科
 
前へ戻る

The rate of reduction in SUVmax between initial PET and after therapy may predict survival in DLBCL

演題番号 : OS-3-152

石井 好美 (Yoshimi Ishii):1、富田 直人 (Naoto Tomita):1、立石 宇貴秀 (Ukihide Tateishi):2、石山 泰史 (Yasufumi Ishiyama):1、山本 恵理 (Eri Yamamoto):1、服部 友歌子 (Yukako Hattori):1、萩原 真紀 (Maki Hagihara):1、山崎 悦子 (Etsuko Yamazaki):1、石ヶ坪 良明 (Yoshiaki Ishigatsubo):1

1:1st Department of Internal Medicine, Yokohama City University Hospital、2:Department of Radiology, Yokohama City University Graduate School of Medicine

 

Background: The rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy dramatically improves the treatment outcome in diffuse large B-cell lymphoma (DLBCL) patients. However, some of patients do not show an improvement in their condition with R-CHOP chemotherapy. Defining prognostic factors are useful to classify DLBCL patients into high risk and not high risk of relapse categories to administer intensive therapy. Recently, the rate of reduction in SUVmax (delta SUVmax) obtained by comparing initial and interim PET scans has been reported to predict survival in DLBCL patients. We evaluated the reduction rate in SUVmax by comparing PET scans before and after R-CHOP therapy. Patients and methods: We retrospectively evaluated delta SUVmax obtained by PET or PET-computed tomography (PET/CT) before and after R-CHOP therapy in 34 newly diagnosed DLBCL patients who were treated at Yokohama City University Hospital. Results: The median follow-up time was 47.3 months. The ROC curve indicated the optimal cutoff as 82% in the prediction of disease progression. The 3-year progression-free survival rate of patients with delta SUVmax >82% and delta SUVmax <82% was 89% and 25%, respectively (P = 0.0005). The 3-year overall-survival rate of patients with delta SUVmax >82% and delta SUVmax < 82% was 100% and 75%, respectively (P = 0.007). Conclusion: The delta SUVmax obtained by comparing PET or PET/CT results before and after R-CHOP therapy could be useful in the prediction of disease progression and survival in newly diagnosed DLBCL patients.

前へ戻る